Sarepta Therapeutics (SRPT) AI Stock Analysis

• Market Cap: $1.27B
• Dividend Yield: N/A
• Average Volume (3M): 11.30M
• Price to Earnings (P/E): 19.6
• Beta (1Y): 0.87
• Revenue Growth: 59.15%
• EPS Growth: -1881.09%
• Country: US
• Employees: 1,372
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -4.60
• Shares Outstanding: 98,277,030
• 10 Day Avg. Volume: 18,382,164
• 30 Day Avg. Volume: 11,299,733
• PEG Ratio: 0.04
• Price to Book (P/B): 1.58
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.65
• Enterprise Value/Market Cap: 2.29
• Enterprise Value/Revenue: 0.40
• Enterprise Value/Gross Profit: 1.60
• Enterprise Value/Ebitda: 6.00
• 1Y Price Target: $21.00
• Price Target Upside: 63.04% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 28

• Rating: 47 Neutral
• Price Target: $13.00 ▲(0.93%Upside)

Sarepta Therapeutics faces significant hurdles with regulatory challenges and financial instability despite strong revenue growth. The bearish technical outlook and negative valuation metrics further weigh on the stock's current attractiveness. Long-term growth potential is acknowledged but overshadowed by immediate risks.

Positive Factors

Ex-US Sales

Roche reported an increase in ex-US Elevidys sales, showing some valuation upside to SRPT stock.

Market Re-entry Probability

There is a 70-80% probability that ELEVIDYS returns to the market in the ambulatory setting following a safety review, with possible modifications to the label including additional screening and monitoring requirements.

Parental Support

Parents are still supportive of ELEVIDYS, and there will be a significant push to get ambulatory use back by parents and advocacy groups.

Negative Factors

FDA Challenges

The path to resumption of Elevidys commercialization may be arduous due to additional clinical data requirements by the FDA.

Financial Pressure

With $1.1B in outstanding convertible debt due in 2027 and cash totaling only $850M, the lack of an immediate-term revenue driver to fill the ELEVIDYS gap highlights the challenges that Sarepta will face to pay back its debt in two years, putting the company under significant financial pressure in the medium-term.

Safety Concerns

Three patient deaths related to acute hepatotoxicity following treatment have been reported, which might influence FDA's decisions.

Sarepta Therapeutics Business Overview & Revenue Model

Company Description

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

How the Company Makes Money

Sarepta Therapeutics generates revenue primarily through the sale of its approved exon-skipping therapies for Duchenne muscular dystrophy. The company earns money by commercializing its products in the U.S. and through strategic partnerships and licensing agreements for international markets. Additionally, Sarepta is involved in research and development collaborations with other pharmaceutical companies and academic institutions, which may provide milestone payments and royalties. The company's earnings are significantly influenced by the successful regulatory approval and market adoption of its therapies, as well as ongoing advancements in its pipeline of genetic medicine candidates.

Sarepta Therapeutics Financial Statement Overview

Summary

Sarepta Therapeutics has shown strong revenue growth, yet faces profitability challenges with negative operating margins and cash flow issues. The stable balance sheet provides some strength, but the company must carefully manage expenses and liquidity.

Income Statement

Sarepta Therapeutics has shown consistent revenue growth, with a notable increase in total revenue from $540 million in 2020 to $2.23 billion in TTM (Trailing-Twelve-Months). The gross profit margin remains strong, yet the company is facing challenges at the operating level with negative EBIT and EBITDA margins, indicating profitability issues. Net profit margin is also negative, pointing towards high operating expenses and potential inefficiencies.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio, reflecting prudent financial leverage but potential exposure to interest rate risks. The equity ratio is stable, suggesting a solid asset base, though return on equity is negative due to net losses. This indicates challenges in generating sufficient returns for shareholders despite asset growth.

Cash Flow

The cash flow statement reveals negative operating and free cash flows, highlighting potential liquidity concerns. The company's ability to convert operating cash flow into net income is weak, with significant cash outflows from operations. Despite negative free cash flow growth, financing activities provide some liquidity cushion.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.90B	1.24B	933.01M	701.89M	540.10M
Gross Profit	1.58B	1.09B	793.02M	604.84M	476.72M
EBITDA	333.06M	-439.20M	-582.12M	-306.08M	-453.38M
Net Income	235.24M	-535.98M	-703.49M	-418.78M	-554.13M
Balance Sheet
Total Assets	3.96B	3.26B	3.13B	3.15B	2.98B
Cash, Cash Equivalents and Short-Term Investments	1.35B	1.68B	1.99B	2.12B	1.94B
Total Debt	1.34B	1.40B	1.62B	1.14B	1.07B
Total Liabilities	2.44B	2.41B	2.74B	2.22B	2.22B
Stockholders Equity	1.53B	859.34M	384.95M	928.01M	761.76M
Cash Flow
Free Cash Flow	-342.74M	-588.34M	-356.17M	-481.66M	25.26M
Operating Cash Flow	-205.79M	-500.99M	-325.35M	-443.17M	107.47M
Investing Cash Flow	755.56M	-165.80M	-1.05B	495.41M	-121.72M
Financing Cash Flow	124.81M	125.00M	232.51M	561.57M	682.32M

Sarepta Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 12.88
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SRPT, the sentiment is Negative. The current price of 12.88 is below the 20-day moving average (MA) of 17.18, below the 50-day MA of 27.22, and below the 200-day MA of 83.67, indicating a bearish trend. The MACD of -3.88 indicates Negative momentum. The RSI at 29.64 is Positive, neither overbought nor oversold. The STOCH value of 14.32 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SRPT.

Sarepta Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ALKS	73 Outperform	$4.37B	12.63	25.71%	―	-12.31%	-17.53%
LEGN	61 Neutral	$8.14B	―	-20.01%	―	112.54%	54.30%
AXSM	54 Neutral	$5.24B	―	-282.16%	―	72.16%	9.65%
Sector *	52 Neutral	$7.61B	0.10	-63.03%	2.08%	16.34%	0.32%
RVMD	52 Neutral	$6.99B	―	-36.68%	―	-100.00%	5.49%
BPMC	50 Neutral	$8.37B	―	-47.71%	―	99.19%	48.43%
SRPT	47 Neutral	$1.27B	19.61	-23.61%	―	59.15%	-1881.09%

Sarepta Therapeutics Corporate Events

Sarepta Faces FDA Hold on Gene Therapy Trials

On July 21, 2025, Sarepta Therapeutics announced that the FDA placed a clinical hold on its investigational gene therapy trials for LGMD, affecting several of its product candidates. This follows a strategic restructuring process announced on July 16, 2025, where the company paused LGMD programs except SRP-9003, for which it completed Phase 3 enrollment and dosing in December 2024. Sarepta plans to discuss with the FDA a potential pathway for accelerated approval of SRP-9003 after the hold is lifted. Additionally, the FDA revoked the platform technology designation for Sarepta’s AAVrh74 platform, initially granted in June 2025.

The most recent analyst rating on (SRPT) stock is a Hold with a $15.00 price target. To see the full list of analyst forecasts on Sarepta Therapeutics stock, see the SRPT Stock Forecast page.

Sarepta Therapeutics Announces Strategic Restructuring Plan

On July 14, 2025, Sarepta Therapeutics announced a strategic restructuring plan, including a 36% workforce reduction, to prioritize high-value programs and ensure long-term financial sustainability. The company aims to save approximately $400 million annually and focus on its siRNA platform, while also updating the ELEVIDYS label with a black box warning for acute liver issues. Key executive appointments were made, and the company reported preliminary second-quarter 2025 financial results, with total net product revenue of $513 million.

The most recent analyst rating on (SRPT) stock is a Buy with a $200.00 price target. To see the full list of analyst forecasts on Sarepta Therapeutics stock, see the SRPT Stock Forecast page.

Sarepta Therapeutics Approves Amendments at Annual Meeting

On June 5, 2025, Sarepta Therapeutics held its annual meeting where stockholders approved amendments to the company’s equity and employee stock purchase plans, increasing the number of shares available under these plans. Additionally, stockholders elected new directors, approved executive compensation, and ratified KPMG as the independent auditor, indicating strong shareholder support for the company’s strategic initiatives and governance.

The most recent analyst rating on (SRPT) stock is a Buy with a $200.00 price target. To see the full list of analyst forecasts on Sarepta Therapeutics stock, see the SRPT Stock Forecast page.